comparemela.com

Latest Breaking News On - Overall survival - Page 10 : comparemela.com

Overall Survival in Patients With Primary Advanced or Recurrent Endometrial Cancer Treated With Dostarlimab Plus Chemotherapy in Part 1 of the ENGOT-EN6-NSGO/GOG-3031/RUBY Trial

Matthew Powell, MD, presents findings from a second interim analysis of part 1 from the ENGOT-EN6-NSGO/GOG-3031/RUBY trial investigating the combination of dostarlimab-gxly plus carboplatin/paclitaxel compared with placebo/chemotherapy in patients with primary advanced or recurrent endometrial cancer.

Matthew powellOverall survivalPatients with primary advancedEndometrial cancerRapid readouts

AstraZeneca : Truqap plus Faslodex approved in Japan for patients with advanced HR-positive breast cancer -March 27, 2024 at 03:09 am EDT

First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations Approval based on CAPItello-291 results which showed.

United kingdomDaiichi sankyoAstrazeneca truqapNational comprehensive cancer networkEuropean unionMerck co incInvestor relations teamWorld health organizationInstitute of cancer researchJapanese ministry of healthEnd results programNational cancer instituteCancer research technologyJapanese ministryNew england journalAstex therapeutics

CStone Pharmaceuticals Reports 2023 Annual Results and Business Updates

SUZHOU, China, March 27, 2024 /PRNewswire/ CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research,

United statesUnited kingdomCity ofHong kongLes laboratoires servierJason yangNational medical products administrationEsmo gi congressChinese medical associationCstone pharmaceuticalsResearch pipeline leveraging multiple sources of innovationChinese society of clinical oncologyInternational financial reporting standardsClinical cancer research3sbio incBlueprint medicines corporation

Recent Data on Axi-Cel in Lymphoma

Dr Leslie discusses two abstracts on axi-cel recently presented at ASH 2023: a subgroup analysis of ZUMA-7 and the 4-year follow-up from ZUMA-5.

Lori leslieJamesk mccloskeyGloria lesliePeer exchangeResearch programsJohn theurer cancer centerHackensack university medical centerHackensack university medicalAssociate professorIndolent lymphomaMash 2023Zuma 7Axi celLargeb cell lymphomaOlder populationCart cell therapy

EFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Topline data from the randomized Phase 2b KICKSTART trial of tomivosertib combined with pembrolizumab in non-small cell lung cancer expected in early April 2024 Median progression free survival of.

United statesKevin gardnerMike tattoryJennifer caswell jinChristian curtisChristopherm calabreseSteve worlandRoberth lurie comprehensive cancer centerNorthwestern universityUniversity of california san franciscoEffector therapeutics incLifesci communicationsExchange commissionDevelopment rd expensesFast trackObjective response rate

vimarsana © 2020. All Rights Reserved.